These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 14709734)

  • 1. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
    Niell BL; Rennert G; Bonner JD; Almog R; Tomsho LP; Gruber SB
    J Natl Cancer Inst; 2004 Jan; 96(1):15-21. PubMed ID: 14709734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
    Kirchhoff T; Satagopan JM; Kauff ND; Huang H; Kolachana P; Palmer C; Rapaport H; Nafa K; Ellis NA; Offit K
    J Natl Cancer Inst; 2004 Jan; 96(1):68-70. PubMed ID: 14709740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
    Rutter JL; Wacholder S; Chetrit A; Lubin F; Menczer J; Ebbers S; Tucker MA; Struewing JP; Hartge P
    J Natl Cancer Inst; 2003 Jul; 95(14):1072-8. PubMed ID: 12865453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
    Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
    Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
    N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
    Agalliu I; Gern R; Leanza S; Burk RD
    Clin Cancer Res; 2009 Feb; 15(3):1112-20. PubMed ID: 19188187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
    Antoniou AC; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
    J Med Genet; 2005 Jul; 42(7):602-3. PubMed ID: 15994883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
    Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K
    J Natl Cancer Inst; 1999 Dec; 91(24):2112-7. PubMed ID: 10601383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.
    Warner E; Foulkes W; Goodwin P; Meschino W; Blondal J; Paterson C; Ozcelik H; Goss P; Allingham-Hawkins D; Hamel N; Di Prospero L; Contiga V; Serruya C; Klein M; Moslehi R; Honeyford J; Liede A; Glendon G; Brunet JS; Narod S
    J Natl Cancer Inst; 1999 Jul; 91(14):1241-7. PubMed ID: 10413426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
    Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
    Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.